Table: q1_q4_2019_prescription_drugs_intro_to_market , manufacturer_name like K*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
Kyowa Kirin, Inc.	42747060290	20 mg 90 Tablet, Film Coated in 1 Bottle	2019-09-19	4500.0000	None	1	None	None	None	None	None	None	None	The estimated number of patients is unknown at this time and an analysis has not been done at this level. An Acquisition Price is N/A as Kyowa Kirin developed the drug.	None
Kyowa Kirin, Inc.	42747060490	40 mg 90 Tablet, Film Coated in 1 Bottle	2019-09-19	4500.0000	None	1	None	None	None	None	None	None	None	The estimated number of patients is unknown at this time and an analysis has not been done at this level. An Acquisition Price is N/A as Kyowa Kirin developed the drug.	None
Karyopharm Therapeutics Inc.	72237010105	XPOVIO (selinexor) 100mg (20 Tablets)	2019-07-03	22000.0000	None	1	6000	None	1	None	None	None	None	None	None
Karyopharm Therapeutics Inc.	72237010101	XPOVIO (selinexor) 60mg (12 Tablets)	2019-07-03	22000.0000	None	1	6000	None	1	None	None	None	None	None	None
Karyopharm Therapeutics Inc.	72237010102	XPOVIO (selinexor) 80mg (16 Tablets)	2019-07-03	22000.0000	None	1	6000	None	1	None	None	None	None	None	None
Karyopharm Therapeutics Inc.	72237010104	XPOVIO (selinexor) 160mg (32 Tablets)	2019-07-03	22000.0000	None	1	6000	None	1	None	None	None	None	None	None
Kadmon Pharmaceuticals, LLC	66435070010	Trientine Hydrochloride Capsules, USP 250 mg (100 capsules)	2019-10-21	15618.0000	Kadmon announced the product’s approval and also made a copay savings card available to eligible patients through healthcare professionals. Kadmon did not otherwise engage in direct-to-consumer marketing, or offer direct-to-consumer promotional incentives or other promotions or advertising to consumers, physicians, or other health professionals with respect to this product. Pricing methodology is based on cost (including development and manufacturing costs) and the market (including the current number of generic competitors and the number of generic competitors expected to enter the market).	None	7000	None	None	None	None	None	None	The prevalence of Wilson’s disease in the US is approximately 7000-9000 patients. Reference: Ferenci P, Askari F. Whom and how to screen for Wilson disease. Expert Rev. Gastroenterol. Hepatol. 8(5), 513-520 (2014). Kadmon developed this product, so acquisition columns have been left blank.	None
Kadmon Pharmaceuticals, LLC	66435070020	Clovique™ (Trientine Hydrochloride Capsules, USP) 250 mg (120 capsules)	2019-10-21	18741.6000	Kadmon announced the product’s approval and also made a copay savings card available to eligible patients. Marketing initiatives include print and digital media, engagement at scientific meetings attended by healthcare providers most likely to manage patients with Wilson’s disease, materials to be used by sales representatives to share information on Clovique with prescribers, and materials to educate patients about Clovique and Wilson’s disease. Pricing methodology is based on cost (including development and manufacturing costs) and the market (including the current number of generic competitors and the number of generic competitors expected to enter the market).	None	7000	None	None	None	None	None	None	The prevalence of Wilson’s disease in the US is approximately 7000-9000 patients. Reference: Ferenci P, Askari F. Whom and how to screen for Wilson disease. Expert Rev. Gastroenterol. Hepatol. 8(5), 513-520 (2014). Kadmon developed this product, so acquisition columns have been left blank.	None